廣生堂(300436.SZ):GST-HG141已完成Ia期臨牀試驗暨確定泰格醫藥為Ib期臨牀試驗CRO
格隆匯2月19日丨廣生堂(300436.SZ)公佈,2021年2月19日,公司與杭州泰格醫藥科技股份有限公司(“泰格醫藥”)簽訂了《技術服務合同》,公司委託泰格醫藥為公司評價GST-HG141片在慢性乙型肝炎患者中多中心、隨機、雙盲、安慰劑對照的多劑量、多次給藥的耐受性、藥代動力學和藥效學Ib期臨牀試驗提供服務。公司將藉助泰格醫藥的平台優勢,加快推進GST-HG141的臨牀研究進度,保障項目的順利進行。
GST-HG141是全新靶點的抗乙肝病毒一類新藥,是乙肝核心蛋白抑制劑,可以抑制HBV(乙肝病毒)衣殼的脱殼與組裝,動物體內藥效試驗展現了優異的病毒抑制作用,是公司乙肝臨牀治癒“登峯計劃”重要組成藥物之一。目前,GST-HG141由病毒性肝炎治療領域著名專家、吉林省肝病研究所所長、吉林大學第一醫院肝病科主任牛俊奇教授以及吉林大學第一醫院I期藥物臨牀試驗病房主任丁豔華教授共同擔任I期臨牀試驗負責人(PI),已完成Ia期臨牀試驗,整體安全性良好。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.